Showing 291-300 of 560 results for "".
Fine Particulate Matter and Eczema
https://practicaldermatology.com/issues/july-2025/fine-particulate-matter-and-eczema/36512/The primary objective of this study was to investigate the potential associations between fine particulate matter (specifically PM2.5) exposure and eczema. Researchers on this study set out to explore whether the odds of having eczema would increase with greater PM2.5 exposure, and to identify whethLiquid Nitrogen Cryotherapy Anesthesia for Botulinum Toxin Injections for Hyperhidrosis
https://practicaldermatology.com/youngmd-connect/resident-resource-center/liquid-nitrogen-cryotherapy-anesthesia-for-botulinum-toxin-injections-for-hyperhidrosis/23687/An accessible but underutilized technique can increase patient comfort.Can AI and Digital Innovation Improve the Patient Experience?
https://practicaldermatology.com/topics/practice-management/can-ai-and-digital-innovation-improve-the-patient-experience/23964/Embrace AI and how it can help improve points of contact with your patients.Physician Spotlight: Peter van de Kerkhof, MD, PhD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-peter-van-de-kerkhof-md-phd/23431/Sunscreen and Dermatologists
https://practicaldermatology.com/topics/practice-management/sunscreen-and-dermatologists/23048/Preparing for Private Equity: Benefits and Drawbacks
https://practicaldermatology.com/issues/september-2025/preparing-for-private-equity-benefits-and-drawbacks/37629/Over the past decade, the health care industry has emerged as a prime target for private equity (PE) investment.Herbals in the Holistic Treatment of Psoriasis
https://practicaldermatology.com/topics/psoriasis/herbals-in-the-holistic-treatment-of-psoriasis/21055/Dermatologists must be aware of the herbal supplements patients may take and their potential effects.Weighing the Prospects of Biosimilars
https://practicaldermatology.com/columns/clinical-focus-1/weighing-the-prospects-of-biosimilars/21477/If they are found to be comparable to the “originators,” biosimilar agents may offer patients significant therapeutic benefits as well as cost efficiency.New Findings Raise Questions About EHRs Going Forward
https://practicaldermatology.com/topics/practice-management/new-findings-raise-questions-about-ehrs-going-forward/22934/A recently published study dampens expectations for the future of EHRs, which may also signal diminished public support.Which Probiotic for Which Disease? Part 1
https://practicaldermatology.com/topics/atopic-dermatitis/which-probiotic-for-which-disease-part-1/23550/Enhanced interest in probiotics means clinicians need to pick the best strain for common dermatologic conditions.